Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
35,033
archived clinical trials in
Lung Cancer

Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy
Status: Enrolling
Updated:  12/22/2017
Clinical Research Facility
mi
from
Goshen, IN
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy
Status: Enrolling
Updated: 12/22/2017
Clinical Research Facility
mi
from
Goshen, IN
Click here to add this to my saved trials
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy
Status: Enrolling
Updated:  12/22/2017
Clinical Research Facility
mi
from
Louisville, KY
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy
Status: Enrolling
Updated: 12/22/2017
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy
Status: Enrolling
Updated:  12/22/2017
Clinical Research Facility
mi
from
Grand Rapids, MI
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy
Status: Enrolling
Updated: 12/22/2017
Clinical Research Facility
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy
Status: Enrolling
Updated:  12/22/2017
Clinical Research Facility
mi
from
Saint Cloud, MN
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy
Status: Enrolling
Updated: 12/22/2017
Clinical Research Facility
mi
from
Saint Cloud, MN
Click here to add this to my saved trials
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy
Status: Enrolling
Updated:  12/22/2017
Clinical Research Facility
mi
from
Las Vegas, NV
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy
Status: Enrolling
Updated: 12/22/2017
Clinical Research Facility
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy
Status: Enrolling
Updated:  12/22/2017
Clinical Research Facility
mi
from
Columbus, OH
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy
Status: Enrolling
Updated: 12/22/2017
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy
Status: Enrolling
Updated:  12/22/2017
Clinical Research Facility
mi
from
Bend, OR
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy
Status: Enrolling
Updated: 12/22/2017
Clinical Research Facility
mi
from
Bend, OR
Click here to add this to my saved trials
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy
Status: Enrolling
Updated:  12/22/2017
Clinical Research Facility
mi
from
Portland, OR
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy
Status: Enrolling
Updated: 12/22/2017
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy
Status: Enrolling
Updated:  12/22/2017
Clinical Research Facility
mi
from
Chattanooga, TN
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy
Status: Enrolling
Updated: 12/22/2017
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy
Status: Enrolling
Updated:  12/22/2017
Clinical Research Facility
mi
from
Knoxville, TN
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy
Status: Enrolling
Updated: 12/22/2017
Clinical Research Facility
mi
from
Knoxville, TN
Click here to add this to my saved trials
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy
Status: Enrolling
Updated:  12/22/2017
Clinical Research Facility
mi
from
Nashville, TN
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy
Status: Enrolling
Updated: 12/22/2017
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy
Status: Enrolling
Updated:  12/22/2017
Clinical Research Facility
mi
from
Dallas, TX
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy
Status: Enrolling
Updated: 12/22/2017
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy
Status: Enrolling
Updated:  12/22/2017
Clinical Research Facility
mi
from
Salt Lake City, UT
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy
Status: Enrolling
Updated: 12/22/2017
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy
Status: Enrolling
Updated:  12/22/2017
Clinical Research Facility
mi
from
Arlington, VA
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy
Status: Enrolling
Updated: 12/22/2017
Clinical Research Facility
mi
from
Arlington, VA
Click here to add this to my saved trials
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy
Status: Enrolling
Updated:  12/22/2017
Clinical Research Facility
mi
from
Seattle, WA
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy
Status: Enrolling
Updated: 12/22/2017
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy
Status: Enrolling
Updated:  12/22/2017
mi
from
Brasschaat,
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy
Status: Enrolling
Updated: 12/22/2017
mi
from
Brasschaat,
Click here to add this to my saved trials
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy
Status: Enrolling
Updated:  12/22/2017
Clinical Research Facility
mi
from
Port Saint Lucie, FL
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy
Status: Enrolling
Updated: 12/22/2017
Clinical Research Facility
mi
from
Port Saint Lucie, FL
Click here to add this to my saved trials
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy
Status: Enrolling
Updated:  12/22/2017
Clinical Research Facility
mi
from
Saint Louis, MO
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy
Status: Enrolling
Updated: 12/22/2017
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy
Status: Enrolling
Updated:  12/22/2017
Investigational Site
mi
from
Redmond, OR
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy
Status: Enrolling
Updated: 12/22/2017
Investigational Site
mi
from
Redmond, OR
Click here to add this to my saved trials
S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery
A Phase II Trial of Novel Oral Anti-Angiogenic Agent AZD2171 (NSC-732208) in Malignant Pleural Mesothelioma
Status: Enrolling
Updated:  12/27/2017
Southwest Oncology Group
mi
from
San Antonio, TX
S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery
A Phase II Trial of Novel Oral Anti-Angiogenic Agent AZD2171 (NSC-732208) in Malignant Pleural Mesothelioma
Status: Enrolling
Updated: 12/27/2017
Southwest Oncology Group
mi
from
San Antonio, TX
Click here to add this to my saved trials
Effect of Multi-Media Enrollment
A Pilot Investigation to Examine the Effect of a Multi-Media, Computer Based Tool (Talking Touchscreen) on Enrollment in Adult Oncology-Specific Clinical Trials at an Academic Medical Center
Status: Enrolling
Updated:  1/2/2018
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Effect of Multi-Media Enrollment
A Pilot Investigation to Examine the Effect of a Multi-Media, Computer Based Tool (Talking Touchscreen) on Enrollment in Adult Oncology-Specific Clinical Trials at an Academic Medical Center
Status: Enrolling
Updated: 1/2/2018
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer
A Phase II Study of Erlotinib (Tarceva) and Hypofractionated Thoracic Radiotherapy for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer
Status: Enrolling
Updated:  1/3/2018
Northeast Radiation Oncology Center
mi
from
Dunmore, PA
A Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer
A Phase II Study of Erlotinib (Tarceva) and Hypofractionated Thoracic Radiotherapy for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer
Status: Enrolling
Updated: 1/3/2018
Northeast Radiation Oncology Center
mi
from
Dunmore, PA
Click here to add this to my saved trials
A Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer
A Phase II Study of Erlotinib (Tarceva) and Hypofractionated Thoracic Radiotherapy for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer
Status: Enrolling
Updated:  1/3/2018
Thomas Jefferson Univeristy
mi
from
Philadelphia, PA
A Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer
A Phase II Study of Erlotinib (Tarceva) and Hypofractionated Thoracic Radiotherapy for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer
Status: Enrolling
Updated: 1/3/2018
Thomas Jefferson Univeristy
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Feasibility Study Using Four-Dimensional CT Imaging for Primary Lung Cancer
A Feasibility Study Using Four-Dimensional CT Imaging to Evaluate Lung Strain in Patients Treated With External Beam Radiation Therapy for Primary Lung Cancer
Status: Enrolling
Updated:  1/3/2018
James Graham Brown Cancer Center
mi
from
Louisville, KY
A Feasibility Study Using Four-Dimensional CT Imaging for Primary Lung Cancer
A Feasibility Study Using Four-Dimensional CT Imaging to Evaluate Lung Strain in Patients Treated With External Beam Radiation Therapy for Primary Lung Cancer
Status: Enrolling
Updated: 1/3/2018
James Graham Brown Cancer Center
mi
from
Louisville, KY
Click here to add this to my saved trials
Real World Data on Gi(l)Otrif® Dose Adjustment
Real-world Data on Gi(l)Otrif® Dose Adjustment in First-line Treatment, TKI-naïve, Advanced Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated:  1/3/2018
Levine Cancer Institute
mi
from
Charlotte, NC
Real World Data on Gi(l)Otrif® Dose Adjustment
Real-world Data on Gi(l)Otrif® Dose Adjustment in First-line Treatment, TKI-naïve, Advanced Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated: 1/3/2018
Levine Cancer Institute
mi
from
Charlotte, NC
Click here to add this to my saved trials
Real World Data on Gi(l)Otrif® Dose Adjustment
Real-world Data on Gi(l)Otrif® Dose Adjustment in First-line Treatment, TKI-naïve, Advanced Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated:  1/3/2018
SMZ Baumgartner Hoehe Otto Wagner Spital
mi
from
Wien,
Real World Data on Gi(l)Otrif® Dose Adjustment
Real-world Data on Gi(l)Otrif® Dose Adjustment in First-line Treatment, TKI-naïve, Advanced Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated: 1/3/2018
SMZ Baumgartner Hoehe Otto Wagner Spital
mi
from
Wien,
Click here to add this to my saved trials
Real World Data on Gi(l)Otrif® Dose Adjustment
Real-world Data on Gi(l)Otrif® Dose Adjustment in First-line Treatment, TKI-naïve, Advanced Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated:  1/3/2018
Montefiore Medical Center
mi
from
Bronx, NY
Real World Data on Gi(l)Otrif® Dose Adjustment
Real-world Data on Gi(l)Otrif® Dose Adjustment in First-line Treatment, TKI-naïve, Advanced Non-small Cell Lung Cancer Patients With EGFR Activating Mutations
Status: Enrolling
Updated: 1/3/2018
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
A Phase II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed Non-small Cell Lung Cancer
Status: Enrolling
Updated:  1/3/2018
St Vincent Regional Cancer Center CCOP
mi
from
Green Bay, WI
Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
A Phase II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed Non-small Cell Lung Cancer
Status: Enrolling
Updated: 1/3/2018
St Vincent Regional Cancer Center CCOP
mi
from
Green Bay, WI
Click here to add this to my saved trials
Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
A Phase II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed Non-small Cell Lung Cancer
Status: Enrolling
Updated:  1/3/2018
Gundersen Lutheran
mi
from
La Crosse, WI
Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
A Phase II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed Non-small Cell Lung Cancer
Status: Enrolling
Updated: 1/3/2018
Gundersen Lutheran
mi
from
La Crosse, WI
Click here to add this to my saved trials
Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
A Phase II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed Non-small Cell Lung Cancer
Status: Enrolling
Updated:  1/3/2018
UW Health Oncology - 1 South Park
mi
from
Madison, WI
Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
A Phase II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed Non-small Cell Lung Cancer
Status: Enrolling
Updated: 1/3/2018
UW Health Oncology - 1 South Park
mi
from
Madison, WI
Click here to add this to my saved trials
Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
A Phase II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed Non-small Cell Lung Cancer
Status: Enrolling
Updated:  1/3/2018
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
A Phase II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed Non-small Cell Lung Cancer
Status: Enrolling
Updated: 1/3/2018
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Click here to add this to my saved trials
Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
A Phase II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed Non-small Cell Lung Cancer
Status: Enrolling
Updated:  1/3/2018
Holy Family Memorial Hospital
mi
from
Manitowoc, WI
Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
A Phase II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed Non-small Cell Lung Cancer
Status: Enrolling
Updated: 1/3/2018
Holy Family Memorial Hospital
mi
from
Manitowoc, WI
Click here to add this to my saved trials
Ketogenic Diet With Chemoradiation for Lung Cancer (KETOLUNG)
A Phase I Trial of a Ketogenic Diet With Concurrent Chemoradiation for Non-small Cell Lung Cancer
Status: Enrolling
Updated:  1/4/2018
Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Ketogenic Diet With Chemoradiation for Lung Cancer (KETOLUNG)
A Phase I Trial of a Ketogenic Diet With Concurrent Chemoradiation for Non-small Cell Lung Cancer
Status: Enrolling
Updated: 1/4/2018
Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Click here to add this to my saved trials
Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer
A Phase II Study of Single Agent Topoisomerase-I Inhibitor Polymer Conjugate, Etirinotecan Pegol (NKTR-102), in Patients With Relapsed Small Cell Lung Cancer
Status: Enrolling
Updated:  1/4/2018
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer
A Phase II Study of Single Agent Topoisomerase-I Inhibitor Polymer Conjugate, Etirinotecan Pegol (NKTR-102), in Patients With Relapsed Small Cell Lung Cancer
Status: Enrolling
Updated: 1/4/2018
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer
A Phase II Study of Single Agent Topoisomerase-I Inhibitor Polymer Conjugate, Etirinotecan Pegol (NKTR-102), in Patients With Relapsed Small Cell Lung Cancer
Status: Enrolling
Updated:  1/4/2018
Rochester General Hospital
mi
from
Rochester, NY
Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer
A Phase II Study of Single Agent Topoisomerase-I Inhibitor Polymer Conjugate, Etirinotecan Pegol (NKTR-102), in Patients With Relapsed Small Cell Lung Cancer
Status: Enrolling
Updated: 1/4/2018
Rochester General Hospital
mi
from
Rochester, NY
Click here to add this to my saved trials
Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer
A Phase II Study of Single Agent Topoisomerase-I Inhibitor Polymer Conjugate, Etirinotecan Pegol (NKTR-102), in Patients With Relapsed Small Cell Lung Cancer
Status: Enrolling
Updated:  1/4/2018
Linden Oaks Medical Campus
mi
from
Rochester, NY
Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer
A Phase II Study of Single Agent Topoisomerase-I Inhibitor Polymer Conjugate, Etirinotecan Pegol (NKTR-102), in Patients With Relapsed Small Cell Lung Cancer
Status: Enrolling
Updated: 1/4/2018
Linden Oaks Medical Campus
mi
from
Rochester, NY
Click here to add this to my saved trials
Abraxane and Alimta in Advanced Solid Tumors
Phase I/II Trial of Abraxane® (ABI-007) and Alimta® (Pemetrexed) in Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer (NSCLC) and Breast Cancer
Status: Enrolling
Updated:  1/5/2018
University of California Davis Cancer Center
mi
from
Sacramento, CA
Abraxane and Alimta in Advanced Solid Tumors
Phase I/II Trial of Abraxane® (ABI-007) and Alimta® (Pemetrexed) in Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer (NSCLC) and Breast Cancer
Status: Enrolling
Updated: 1/5/2018
University of California Davis Cancer Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Clinical Study of Microdosing Carboplatin in Lung or Bladder Cancer
A Phase 0 Clinical Trial of Microdosing Carboplatin and Molecular Profiling for Chemoresistance
Status: Enrolling
Updated:  1/5/2018
University of California-Davis
mi
from
Sacramento, CA
Clinical Study of Microdosing Carboplatin in Lung or Bladder Cancer
A Phase 0 Clinical Trial of Microdosing Carboplatin and Molecular Profiling for Chemoresistance
Status: Enrolling
Updated: 1/5/2018
University of California-Davis
mi
from
Sacramento, CA
Click here to add this to my saved trials
Clinical Study of Microdosing Carboplatin in Lung or Bladder Cancer
A Phase 0 Clinical Trial of Microdosing Carboplatin and Molecular Profiling for Chemoresistance
Status: Enrolling
Updated:  1/5/2018
University of California at Los Angeles
mi
from
Los Angeles, CA
Clinical Study of Microdosing Carboplatin in Lung or Bladder Cancer
A Phase 0 Clinical Trial of Microdosing Carboplatin and Molecular Profiling for Chemoresistance
Status: Enrolling
Updated: 1/5/2018
University of California at Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors
Phase I Trial of Cisplatin and Pemetrexed in Combination With Panobinostat in Advanced Solid Tumors, With Emphasis on Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/5/2018
University of California Davis Cancer Center
mi
from
Sacramento, CA
Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors
Phase I Trial of Cisplatin and Pemetrexed in Combination With Panobinostat in Advanced Solid Tumors, With Emphasis on Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/5/2018
University of California Davis Cancer Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors
Phase I Trial of Cisplatin and Pemetrexed in Combination With Panobinostat in Advanced Solid Tumors, With Emphasis on Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/5/2018
Henry Ford Health System
mi
from
Detroit, MI
Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors
Phase I Trial of Cisplatin and Pemetrexed in Combination With Panobinostat in Advanced Solid Tumors, With Emphasis on Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/5/2018
Henry Ford Health System
mi
from
Detroit, MI
Click here to add this to my saved trials
Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer
Phase II Study of Dovitinib and Pilot Study of Fibroblast Growth Factor Receptor Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer Previously Treated With Anti-Vascular Endothelial Growth Factor Therapy
Status: Enrolling
Updated:  1/5/2018
University of California Comprehensive Cancer Center
mi
from
Sacramento, CA
Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer
Phase II Study of Dovitinib and Pilot Study of Fibroblast Growth Factor Receptor Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer Previously Treated With Anti-Vascular Endothelial Growth Factor Therapy
Status: Enrolling
Updated: 1/5/2018
University of California Comprehensive Cancer Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer
Phase I Trial of Cisplatin and Etoposide Plus BKM120 in Advanced Solid Tumors, With an Emphasis on Small Cell Lung Cancer
Status: Enrolling
Updated:  1/5/2018
University of California Davis Cancer Center
mi
from
Sacramento, CA
Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer
Phase I Trial of Cisplatin and Etoposide Plus BKM120 in Advanced Solid Tumors, With an Emphasis on Small Cell Lung Cancer
Status: Enrolling
Updated: 1/5/2018
University of California Davis Cancer Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Irreversible Electroporation Ablation for Colorectal Metastases to the Lung
Irreversible Electroporation Ablation for Colorectal Metastases to the Lung
Status: Enrolling
Updated:  1/5/2018
Memorial Sloan Kettering at Basking Ridge
mi
from
Basking Ridge, NJ
Irreversible Electroporation Ablation for Colorectal Metastases to the Lung
Irreversible Electroporation Ablation for Colorectal Metastases to the Lung
Status: Enrolling
Updated: 1/5/2018
Memorial Sloan Kettering at Basking Ridge
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
Irreversible Electroporation Ablation for Colorectal Metastases to the Lung
Irreversible Electroporation Ablation for Colorectal Metastases to the Lung
Status: Enrolling
Updated:  1/5/2018
Memorial Sloan-Kettering Cancer Center @ Suffolk
mi
from
Commack, NY
Irreversible Electroporation Ablation for Colorectal Metastases to the Lung
Irreversible Electroporation Ablation for Colorectal Metastases to the Lung
Status: Enrolling
Updated: 1/5/2018
Memorial Sloan-Kettering Cancer Center @ Suffolk
mi
from
Commack, NY
Click here to add this to my saved trials
Irreversible Electroporation Ablation for Colorectal Metastases to the Lung
Irreversible Electroporation Ablation for Colorectal Metastases to the Lung
Status: Enrolling
Updated:  1/5/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Irreversible Electroporation Ablation for Colorectal Metastases to the Lung
Irreversible Electroporation Ablation for Colorectal Metastases to the Lung
Status: Enrolling
Updated: 1/5/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Irreversible Electroporation Ablation for Colorectal Metastases to the Lung
Irreversible Electroporation Ablation for Colorectal Metastases to the Lung
Status: Enrolling
Updated:  1/5/2018
Memorial Sloan Kettering West Harrison
mi
from
Harrison, NY
Irreversible Electroporation Ablation for Colorectal Metastases to the Lung
Irreversible Electroporation Ablation for Colorectal Metastases to the Lung
Status: Enrolling
Updated: 1/5/2018
Memorial Sloan Kettering West Harrison
mi
from
Harrison, NY
Click here to add this to my saved trials
Everolimus, Carboplatin, and Etoposide in Treating Patients With Small Cell Lung Cancer or Other Advanced Solid Tumors
Phase I Trial of Carboplatin and Etoposide in Combination With Everolimus (RAD001) in Advanced Solid Tumors, With Emphasis on Small Cell Lung Cancer (SCLC)
Status: Enrolling
Updated:  1/5/2018
University of California Davis Cancer Center
mi
from
Sacramento, CA
Everolimus, Carboplatin, and Etoposide in Treating Patients With Small Cell Lung Cancer or Other Advanced Solid Tumors
Phase I Trial of Carboplatin and Etoposide in Combination With Everolimus (RAD001) in Advanced Solid Tumors, With Emphasis on Small Cell Lung Cancer (SCLC)
Status: Enrolling
Updated: 1/5/2018
University of California Davis Cancer Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Irinotecan and Carboplatin in Treating Patients With Metastatic or Recurrent Small Cell Lung Cancer
Phase II Study of Irinotecan and Carboplatin in Metastatic or Relapsed Small-Cell Lung Cancer
Status: Enrolling
Updated:  1/5/2018
University of California Davis Cancer Center
mi
from
Sacramento, CA
Irinotecan and Carboplatin in Treating Patients With Metastatic or Recurrent Small Cell Lung Cancer
Phase II Study of Irinotecan and Carboplatin in Metastatic or Relapsed Small-Cell Lung Cancer
Status: Enrolling
Updated: 1/5/2018
University of California Davis Cancer Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
A Phase II Study of Induction Chemotherapy Followed by Thoracic Radiotherapy and Erlotinib in Poor-Risk Stage III Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  1/8/2018
East Bay Radiation Oncology Center
mi
from
Castro Valley, CA
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
A Phase II Study of Induction Chemotherapy Followed by Thoracic Radiotherapy and Erlotinib in Poor-Risk Stage III Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 1/8/2018
East Bay Radiation Oncology Center
mi
from
Castro Valley, CA
Click here to add this to my saved trials